MaxCyte, Inc MXCT 深 滬
已收盤 08-15 16:00:00 美东时间
1.36
-0.050
-3.55%
華盛通- 最 高1.45
- 今 開1.43
- 成交量 91.75万股
- 最 低 1.35
- 昨 收 1.41
- 總市值 1.46亿
- 52周最高 5.20
- 市盈率 靜 --
- 換手率 0.86%
- 52周最低 1.26
- 委 比 36.07%
- 總股本 1.07亿
- 歷史最高 17.44
- 量 比 0.57
- 振 幅 7.09%
- 歷史最低 1.26
- 每 手 1
- 風險率 0.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多A Preview Of Bionano Genomics's Earnings
Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings rep...
08-14 02:02
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement
An announcement from MaxCyte ( ($MXCT) ) is now available. On August 11, 2025, ...
08-12 05:08
A Look Ahead: Rapid Micro Biosystems's Earnings Forecast
Rapid Micro Biosystems (NASDAQ:RPID) is gearing up to announce its quarterly ea...
08-12 02:01
BTIG Downgrades MaxCyte to Neutral
BTIG analyst Mark Massaro downgrades MaxCyte (NASDAQ:MXCT) from Buy to Neutral.
08-11 19:42
William Blair Downgrades MaxCyte to Market Perform
William Blair analyst Matt Larew downgrades MaxCyte (NASDAQ:MXCT) from Outperform to Market Perform.
08-07 18:47
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
MaxCyte signs platform license agreement with Adicet Bio
MaxCyte (NASDAQ:MXCT) said on Monday that it has signed a strategic platform license with Adicet Bio, a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for ...
08-04 20:57
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte and Anocca AB have signed a Strategic Platform License Agreement (SPL) enabling Anocca to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for the development and manufacturing of TCR-T cell therapies. Anocca gains non-exclusive rights for research, clinical, and commercial use, while MaxCyte will receive annual licensing fees and program-related revenue. This collaboration aims to enhance Anocca’s ability to deliver ge...
07-31 12:05
Stephens & Co. Assumes MaxCyte at Overweight, Announces Price Target of $6
Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating and announces Price Target of $6.
07-22 23:05
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
MaxCyte, Inc. announced it will release its second-quarter 2025 financial results after the U.S. market close on August 6, 2025. Management will host a conference call at 4:30 p.m. ET to discuss the results. Investors must register online in advance, and a live or archived webcast will be available on the company's website. MaxCyte, a leader in cell-engineering technologies, provides innovative solutions for next-generation cell therapies.
07-09 12:05
